<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">32134730</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>11</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1558-9544</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>23</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>03</Month>
                        <Day>05</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Forum for health economics &amp; policy</Title>
                <ISOAbbreviation>Forum Health Econ Policy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cost-Effectiveness and Estimated Health Benefits of Treating Patients with Vitamin D in Pre-Dialysis.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1515/fhep-2019-0020</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">/j/fhep.2020.23.issue-1/fhep-2019-0020/fhep-2019-0020.xml</ELocationID>
            <Abstract>
                <AbstractText>Background The optimal timing of treatment with vitamin D therapy for patients with chronic kidney disease (CKD), vitamin D insufficiency, and secondary hyperparathyroidism (SHPT) is a pressing question in nephrology with economic and patient outcome implications. Objective The objective of this study was to estimate the cost-effectiveness of earlier vitamin D treatment in CKD patients not on dialysis with vitamin D insufficiency and SHPT. Design A cost-effectiveness analysis based on a Markov model of CKD progression was developed from the Medicare perspective. The model follows a hypothetical cohort of 1000 Stage 3 or 4 CKD patients over a 5-year time horizon. The intervention was vitamin D therapy initiated in CKD stages 3 or 4 through CKD stage 5/end-stage renal disease (ESRD) versus initiation in CKD stage 5/ESRD only. The outcomes of interest were cardiovascular (CV) events averted, fractures averted, time in CKD stage 5/ESRD, mortality, quality-adjusted life years (QALYs), and costs associated with clinical events and CKD stage. Results Vitamin D treatment in CKD stages 3 and 4 was a dominant strategy when compared to waiting to treat until CKD stage 5/ESRD. Total cost savings associated with treatment during CKD stages 3 and 4, compared to waiting until CKD stage 5/ESRD, was estimated to be $19.9 million. The model estimated that early treatment results in 159 averted CV events, 5 averted fractures, 269 fewer patient-years in CKD stage 5, 41 fewer deaths, and 191 additional QALYs. Conclusions Initiating vitamin D therapy in CKD stages 3 or 4 appears to be cost-effective, largely driven by the annual costs of care by CKD stage, CV event costs, and risks of hypercalcemia. Further research demonstrating causal relationships between vitamin D therapy and patient outcomes is needed to inform decision making regarding vitamin D therapy timing.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Snyder</LastName>
                    <ForeName>Sophie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>BluePath Solutions, 10951 W. Pico Blvd. Suite 120 Los Angeles, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hollenbeak</LastName>
                    <ForeName>Christopher S</ForeName>
                    <Initials>CS</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Pennsylvania State University, Department of Health Policy and Administration, University Park, PA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kalantar-Zadeh</LastName>
                    <ForeName>Kamyar</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Medicine, University of California, Irvine, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gitlin</LastName>
                    <ForeName>Matthew</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>BluePath Solutions, 10951 W. Pico Blvd. Suite 120 Los Angeles, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ashfaq</LastName>
                    <ForeName>Akhtar</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical R &amp; D and Medical Affairs, Renal Division, Opko Pharmaceuticals, Miami, FL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>03</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Forum Health Econ Policy</MedlineTA>
            <NlmUniqueID>101316961</NlmUniqueID>
            <ISSNLinking>1558-9544</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>H</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">25-hydroxyvitamin D</Keyword>
            <Keyword MajorTopicYN="Y">cardiovascular disease</Keyword>
            <Keyword MajorTopicYN="Y">chronic kidney disease (CKD)</Keyword>
            <Keyword MajorTopicYN="Y">cost-effectiveness</Keyword>
            <Keyword MajorTopicYN="Y">disease progression</Keyword>
            <Keyword MajorTopicYN="Y">economic analysis</Keyword>
            <Keyword MajorTopicYN="Y">end-stage renal disease (ESRD)</Keyword>
            <Keyword MajorTopicYN="Y">fracture</Keyword>
            <Keyword MajorTopicYN="Y">health care costs</Keyword>
            <Keyword MajorTopicYN="Y">parathyroid hormone (PTH)</Keyword>
            <Keyword MajorTopicYN="Y">pre-dialysis care</Keyword>
            <Keyword MajorTopicYN="Y">secondary hyperparathyroidism (SHPT)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>3</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>3</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>3</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">32134730</ArticleId>
            <ArticleId IdType="doi">10.1515/fhep-2019-0020</ArticleId>
            <ArticleId IdType="pii">/j/fhep.ahead-of-print/fhep-2019-0020/fhep-2019-0020.xml</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>